Genoway SA
PAR:ALGEN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Genoway SA
Capital Expenditures
Genoway SA
Capital Expenditures Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Genoway SA
PAR:ALGEN
|
Capital Expenditures
-€9.8m
|
CAGR 3-Years
-57%
|
CAGR 5-Years
-47%
|
CAGR 10-Years
-53%
|
|
|
Valneva SE
PAR:VLA
|
Capital Expenditures
-€4.5m
|
CAGR 3-Years
47%
|
CAGR 5-Years
25%
|
CAGR 10-Years
-5%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Capital Expenditures
-€3.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-31%
|
CAGR 10-Years
-16%
|
|
|
Inventiva SA
PAR:IVA
|
Capital Expenditures
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Capital Expenditures
-$538k
|
CAGR 3-Years
11%
|
CAGR 5-Years
28%
|
CAGR 10-Years
19%
|
|
|
Abivax SA
PAR:ABVX
|
Capital Expenditures
-€643k
|
CAGR 3-Years
-26%
|
CAGR 5-Years
6%
|
CAGR 10-Years
5%
|
|
Genoway SA
Glance View
genOway SA engages in the development of genetically-modified mouse, rat, and cellular models for biopharmaceutical and research companies. The company is headquartered in Lyon, Auvergne-Rhone-Alpes. The company went IPO on 2007-05-04. The firm offers an array of services which include site specific transgenesis, random insertion based transgenic models, gene overexpression, humanization, gene deletion and gene knock-down (RNA interference). The Company’s clients include multinational biopharmaceutical companies, such as Roche, Novartis and Servier, as well as universities and research institutes, notably Boston University, University of Tokyo, Johann Wolfgang Goethe University Hospital Frankfurt and Centre National de Genotypage.
See Also
What is Genoway SA's Capital Expenditures?
Capital Expenditures
-9.8m
EUR
Based on the financial report for Jun 30, 2025, Genoway SA's Capital Expenditures amounts to -9.8m EUR.
What is Genoway SA's Capital Expenditures growth rate?
Capital Expenditures CAGR 10Y
-53%
Over the last year, the Capital Expenditures growth was -312%. The average annual Capital Expenditures growth rates for Genoway SA have been -57% over the past three years , -47% over the past five years , and -53% over the past ten years .
